Sun Pharma enters into exclusive licensing agreement with Lundbeck

5 Apr 2022 , 01:33 AM

Sun Pharmaceuticals Industries announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H Lundbeck AS Lundbeck to market and distribute its own version of Vortioxetine in India under the brand name VORTIDIFtrade; The territory of the licensing agreement will only cover India Vortioxetine is a novel antidepressant with multimodal activity which is approved to treat Major Depressive Disorder MDD in adults The product is approved in over 80 countries including the US EU Canada and Australia